SPC
CUE icon

Sigma Planning Corp’s Cue Biopharma CUE Stock Holding History

Sigma Planning Corp’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,292
Closed -$8.91K – 1417
2026
Q1 		$8.91K Sell
1,292
-76
-6% -$709 ﹤0.01% 1306
2025
Q4 		$12.5K Sell
1,368
-409
-23% -$7.51K ﹤0.01% 1291
2025
Q3 		$38.3K Sell
1,777
-73
-4% -$1.71K ﹤0.01% 1282
2025
Q2 		$37.9K Sell
1,850
-9,025
-83% -$193K ﹤0.01% 1235
2025
Q1 		$297K Sell
10,875
-4,031
-27% -$150K 0.01% 951
2024
Q4 		$487K Buy
14,906
+1,528
+11% +$57.4K 0.02% 752
2024
Q3 		$304K Buy
13,378
+4,510
+51% +$97.7K 0.01% 945
2024
Q2 		$330K Buy
8,868
+334
+4% +$16.5K 0.01% 885
2024
Q1 		$484K Buy
8,534
+4,905
+135% +$346K 0.02% 776
2023
Q4 		$287K Sell
3,629
-4,528
-56% -$324K 0.02% 634
2023
Q3 		$563K Buy
8,157
+647
+9% +$63.2K 0.02% 660
2023
Q2 		$822K Buy
7,510
+147
+2% +$17.3K 0.03% 538
2023
Q1 		$789K Buy
7,363
+939
+15% +$89.6K 0.03% 610
2022
Q4 		$549K Buy
6,424
+143
+2% +$13.1K 0.02% 729
2022
Q3 		$420K Buy
6,281
+711
+13% +$61.2K 0.02% 802
2022
Q2 		$416K Buy
5,570
+1,246
+29% +$146K 0.01% 828
2022
Q1 		$633K Buy
4,324
+1,461
+51% +$310K 0.02% 741
2021
Q4 		$971K Buy
2,863
+55
+2% +$21.3K 0.03% 557
2021
Q3 		$1.23M Buy
2,808
+85
+3% +$29.6K 0.04% 475
2021
Q2 		$952K Buy
2,723
+287
+12% +$111K 0.03% 571
2021
Q1 		$892K Buy
2,436
+50
+2% +$20.6K 0.03% 549
2020
Q4 		$895K Buy
2,386
+392
+20% +$157K 0.03% 472
2020
Q3 		$900K Buy
1,994
+225
+13% +$130K 0.04% 428
2020
Q2 		$1.3M Sell
1,769
-439
-20% -$318K 0.06% 321
2020
Q1 		$940K Buy
2,208
+29
+1% +$14.1K 0.06% 335
2019
Q4 		$1.04M Buy
2,179
+172
+9% +$54K 0.04% 394
2019
Q3 		$508K Buy
2,007
+413
+26% +$99.2K 0.02% 566
2019
Q2 		$430K Buy
1,594
+191
+14% +$47.5K 0.02% 595
2019
Q1 		$325K Buy
+1,403
New +$267K 0.02% 648

Other funds holding CUE

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM

Sigma Planning Corp's CUE Position: Q2 2026 in Review

Sigma Planning Corp sold out of Cue Biopharma (CUE) in Q2 2026, closing a stake of 1,292 shares — an estimated $8.91K sold.

Sigma Planning Corp first reported a position in CUE in Q1 2019 and held it in 29 quarters. The position peaked at $1.3M in Q2 2020. 49 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • Sigma Planning Corp reported no remaining Cue Biopharma position as of Q2 2026 after selling out during the quarter.
  • Sigma Planning Corp sold 1,292 Cue Biopharma shares in Q2 2026, an estimated $8.91K.
  • Sigma Planning Corp first reported a position in Cue Biopharma in Q1 2019 and held it in 29 quarters.
  • Sigma Planning Corp's Cue Biopharma position peaked at $1.3M in Q2 2020.
  • 49 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Sigma Planning Corp's 13F filing for Q2 2026, filed 7 Aug 2026.